


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app19.us.archive.org';v.server_ms=516;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Guideline on the management of bleeding in patients on antithrombotic agents. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712194818im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712194818im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712194818im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712194818im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712194818/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712194818im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712194818cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712194818js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712194818if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712194818/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712194818if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712194818/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712194818/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712194818/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712194818/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712194818/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712194818/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712194818/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712194818/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712194818/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712194818/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712194818/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712194818/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712194818/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712194818/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712194818/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712194818/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712194818/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712194818/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712194818/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712194818/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:009478</li>
            <li>2013 Jan
            </li>            
                                </ul>
        <div>
                <h1>Guideline on the management of bleeding in patients on antithrombotic agents.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712194818/https://www.guideline.gov/search?f_Guideline_Developer_String=British%20Society%20for%20Haematology%20Guidelines&amp;fLockTerm=British%2BSociety%2Bfor%2BHaematology%2BGuidelines">British Society for Haematology Guidelines</a></li>
                        <li>   
                                <a id="1851" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013 Jan;160(1):35-46. <a href="https://web.archive.org/web/20180712194818/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23116425" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712194818im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180712194818/https://www.guideline.gov/Home/Disclaimer?id=38947&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.bcshguidelines.com%252fdocuments%252fbleeding_on_antithrombotics_Makris_2012.pdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712194818im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180712194818/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_ICD9CM_CUI=C0019004&amp;fLockTerm=Hemodialysis">Hemodialysis</a>
 (39.95), <a href="/web/20180712194818/https://www.guideline.gov/search?f_ICD9CM_CUI=C0019080&amp;fLockTerm=Hemorrhage%2c+unspecified">Hemorrhage, unspecified</a>
 (459.0), <a href="/web/20180712194818/https://www.guideline.gov/search?f_ICD9CM_CUI=C0032134&amp;fLockTerm=Therapeutic+plasmapheresis">Therapeutic plasmapheresis</a>
 (99.71), <a href="/web/20180712194818/https://www.guideline.gov/search?f_ICD9CM_CUI=C0086818&amp;fLockTerm=Transfusion+of+platelets">Transfusion of platelets</a>
 (99.05)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0003280&amp;fLockTerm=Anticoagulants">Anticoagulants</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0005789&amp;fLockTerm=Blood+Coagulation+Factors">Blood Coagulation Factors</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0005790&amp;fLockTerm=Blood+Coagulation+Tests">Blood Coagulation Tests</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0007955&amp;fLockTerm=Charcoal">Charcoal</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0015502&amp;fLockTerm=Factor+VII">Factor VII</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0015506&amp;fLockTerm=Factor+VIII">Factor VIII</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0016006&amp;fLockTerm=Fibrinogen">Fibrinogen</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0016018&amp;fLockTerm=Fibrinolytic+Agents">Fibrinolytic Agents</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0016055&amp;fLockTerm=Fibronectins">Fibronectins</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019014&amp;fLockTerm=Hemofiltration">Hemofiltration</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019063&amp;fLockTerm=Hemoperfusion">Hemoperfusion</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019080&amp;fLockTerm=Hemorrhage">Hemorrhage</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019116&amp;fLockTerm=Hemostasis">Hemostasis</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019120&amp;fLockTerm=Hemostatics">Hemostatics</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019134&amp;fLockTerm=Heparin">Heparin</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0019139&amp;fLockTerm=Heparin%2c+Low-Molecular-Weight">Heparin, Low-Molecular-Weight</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0030679&amp;fLockTerm=Patient+Care+Team">Patient Care Team</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0032105&amp;fLockTerm=Plasma">Plasma</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0032134&amp;fLockTerm=Plasmapheresis">Plasmapheresis</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0032177&amp;fLockTerm=Platelet+Aggregation+Inhibitors">Platelet Aggregation Inhibitors</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0086818&amp;fLockTerm=Platelet+Transfusion">Platelet Transfusion</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0033603&amp;fLockTerm=Protamines">Protamines</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0040044&amp;fLockTerm=Thrombolytic+Therapy">Thrombolytic Therapy</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0040613&amp;fLockTerm=Tranexamic+Acid">Tranexamic Acid</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0042878&amp;fLockTerm=Vitamin+K">Vitamin K</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MSH_CUI=C0871549&amp;fLockTerm=Withholding+Treatment">Withholding Treatment</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0003280&amp;fLockTerm=Anticoagulants">Anticoagulants</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0005789&amp;fLockTerm=Blood+Coagulation+Factor">Blood Coagulation Factor</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0005790&amp;fLockTerm=Blood+coagulation+tests">Blood coagulation tests</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0015502&amp;fLockTerm=Factor+VII">Factor VII</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0015506&amp;fLockTerm=Factor+VIII">Factor VIII</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0016006&amp;fLockTerm=Fibrinogen">Fibrinogen</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0016018&amp;fLockTerm=Fibrinolytic+Agents">Fibrinolytic Agents</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0016055&amp;fLockTerm=Fibronectins">Fibronectins</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0016709&amp;fLockTerm=Fresh+frozen+plasma">Fresh frozen plasma</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019004&amp;fLockTerm=Hemodialysis">Hemodialysis</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019080&amp;fLockTerm=Hemorrhage">Hemorrhage</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019120&amp;fLockTerm=Hemostatic+Agents">Hemostatic Agents</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019116&amp;fLockTerm=Hemostatic+function">Hemostatic function</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019134&amp;fLockTerm=Heparin">Heparin</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0019139&amp;fLockTerm=Heparin%2c+Low-Molecular-Weight">Heparin, Low-Molecular-Weight</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0032105&amp;fLockTerm=Plasma">Plasma</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0032134&amp;fLockTerm=Plasmapheresis">Plasmapheresis</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0032177&amp;fLockTerm=Platelet+Aggregation+Inhibitors">Platelet Aggregation Inhibitors</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0033602&amp;fLockTerm=Protamine+Sulfate+(USP)">Protamine Sulfate (USP)</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0072434&amp;fLockTerm=prothrombin+complex+concentrates">prothrombin complex concentrates</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_MTH_CUI=C0042878&amp;fLockTerm=Vitamin+K">Vitamin K</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0005790&amp;fLockTerm=coagulation+studies">coagulation studies</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0019134&amp;fLockTerm=heparin">heparin</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0032134&amp;fLockTerm=plasmapheresis">plasmapheresis</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0086818&amp;fLockTerm=platelet+transfusion">platelet transfusion</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0040044&amp;fLockTerm=thrombolytic+therapy">thrombolytic therapy</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_PDQ_CUI=C0040613&amp;fLockTerm=tranexamic+acid">tranexamic acid</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0288672&amp;fLockTerm=Abciximab">Abciximab</a>
 (108974006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0288672&amp;fLockTerm=Abciximab">Abciximab</a>
 (386951001), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001275&amp;fLockTerm=Activated+charcoal">Activated charcoal</a>
 (32519007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001275&amp;fLockTerm=Activated+charcoal">Activated charcoal</a>
 (398628008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003280&amp;fLockTerm=Anticoagulant">Anticoagulant</a>
 (372862008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003280&amp;fLockTerm=Anticoagulant">Anticoagulant</a>
 (81839001), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0457504&amp;fLockTerm=Anticoagulant-induced+bleeding">Anticoagulant-induced bleeding</a>
 (278365007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005789&amp;fLockTerm=Blood+clotting+factor">Blood clotting factor</a>
 (350475008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005790&amp;fLockTerm=Blood+coagulation+panel">Blood coagulation panel</a>
 (3116009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0015502&amp;fLockTerm=Coagulation+factor+VII">Coagulation factor VII</a>
 (30804005), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0443121&amp;fLockTerm=Cryoprecipitate">Cryoprecipitate</a>
 (256401009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0443121&amp;fLockTerm=Cryoprecipitate">Cryoprecipitate</a>
 (420599006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016006&amp;fLockTerm=Factor+I">Factor I</a>
 (23295004), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016006&amp;fLockTerm=Factor+I">Factor I</a>
 (259790000), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0072434&amp;fLockTerm=Factor+IX+fraction">Factor IX fraction</a>
 (319905006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0015506&amp;fLockTerm=Factor+VIII">Factor VIII</a>
 (278910002), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0015506&amp;fLockTerm=Factor+VIII">Factor VIII</a>
 (416523005), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016055&amp;fLockTerm=Fibronectin">Fibronectin</a>
 (69313002), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016709&amp;fLockTerm=Fresh+frozen+plasma">Fresh frozen plasma</a>
 (346447007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019004&amp;fLockTerm=Hemodialysis">Hemodialysis</a>
 (302497006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019014&amp;fLockTerm=Hemofiltration">Hemofiltration</a>
 (233581009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019063&amp;fLockTerm=Hemoperfusion">Hemoperfusion</a>
 (233591003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0181185&amp;fLockTerm=Hemoperfusion+system">Hemoperfusion system</a>
 (462861004), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019080&amp;fLockTerm=Hemorrhage">Hemorrhage</a>
 (131148009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019080&amp;fLockTerm=Hemorrhage">Hemorrhage</a>
 (50960005), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019120&amp;fLockTerm=Hemostatic+agent">Hemostatic agent</a>
 (26370007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019120&amp;fLockTerm=Hemostatic+agent">Hemostatic agent</a>
 (372681003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019120&amp;fLockTerm=Hemostatic+agent">Hemostatic agent</a>
 (705689008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019116&amp;fLockTerm=Hemostatic+function">Hemostatic function</a>
 (74848003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019134&amp;fLockTerm=Heparin">Heparin</a>
 (372877000), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019134&amp;fLockTerm=Heparin">Heparin</a>
 (84812008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019134&amp;fLockTerm=Heparin">Heparin</a>
 (96382006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019139&amp;fLockTerm=Low+molecular+weight+heparin">Low molecular weight heparin</a>
 (373294004), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019139&amp;fLockTerm=Low+molecular+weight+heparin">Low molecular weight heparin</a>
 (87233003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032105&amp;fLockTerm=Plasma">Plasma</a>
 (419185008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032105&amp;fLockTerm=Plasma">Plasma</a>
 (50863008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032134&amp;fLockTerm=Plasmapheresis">Plasmapheresis</a>
 (20720000), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0086818&amp;fLockTerm=Platelet+transfusion">Platelet transfusion</a>
 (12719002), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0086818&amp;fLockTerm=Platelet+transfusion">Platelet transfusion</a>
 (180208003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033603&amp;fLockTerm=Protamine">Protamine</a>
 (350083007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033603&amp;fLockTerm=Protamine">Protamine</a>
 (372630008), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033602&amp;fLockTerm=Protamine+sulfate">Protamine sulfate</a>
 (64520006), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016018&amp;fLockTerm=Thrombolytic">Thrombolytic</a>
 (303960004), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016018&amp;fLockTerm=Thrombolytic">Thrombolytic</a>
 (372742009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040044&amp;fLockTerm=Thrombolytic+therapy">Thrombolytic therapy</a>
 (426347000), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040613&amp;fLockTerm=Tranexamic+acid">Tranexamic acid</a>
 (109006003), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040613&amp;fLockTerm=Tranexamic+acid">Tranexamic acid</a>
 (386960009), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042878&amp;fLockTerm=Vitamin+K">Vitamin K</a>
 (65183007), <a href="/web/20180712194818/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042878&amp;fLockTerm=Vitamin+K">Vitamin K</a>
 (74226000)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SPN</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_SPN_CUI=C0181185&amp;fLockTerm=APPARATUS%2c+HEMOPERFUSION%2c+SORBENT">APPARATUS, HEMOPERFUSION, SORBENT</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_SPN_CUI=C0019134&amp;fLockTerm=HEPARIN">HEPARIN</a>
, <a href="/web/20180712194818/https://www.guideline.gov/search?f_SPN_CUI=C0033602&amp;fLockTerm=PROTAMINE+SULPHATE">PROTAMINE SULPHATE</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180712194818/https://www.guideline.gov/search?f_UMD_CUI=C0181185&amp;fLockTerm=Hemoperfusion+Systems">Hemoperfusion Systems</a>
 (12-001)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#430" class="section-mark">Contraindications</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/downloadcontent/ngc-9478?contentType=pdf" class="pdf">.PDF 88.1 kb</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/downloadcontent/ngc-9478?contentType=word" class="word">Word Document 286.4 kb</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/downloadcontent/ngc-9478?contentType=xml" class="xml">.XML 37.0 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712194818/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712194818/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712194818/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712194818/mailto:/?Subject=AHRQ: Guideline on the management of bleeding in patients on antithrombotic agents.&amp;body=https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Guideline on the management of bleeding in patients on antithrombotic agents. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Jan 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947">RefWorks</a></li>
                            <li><a href="/web/20180712194818/https://www.guideline.gov/summaries/citedownload/38947?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="38947" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions for the quality of the evidence (<strong>A-C</strong>) and strength of recommendation (strong [grade <strong>1</strong>], weak [grade <strong>2</strong>]) are given at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Specific Measures</strong></span></p>
<p><strong>Parenteral Anticoagulants</strong></p>
<p><em>Unfractionated Heparin (UFH)</em></p>
<ul style="list-style-type: disc;">
    <li>Stopping an UFH infusion and general haemostatic measures are often sufficient to stop or prevent bleeding (<strong>2C</strong>). </li>
    <li>Protamine sulphate (1 mg per 80&ndash;100 units UFH) will fully reverse UFH, but should be given slower than 5 mg/min to minimize the risk of adverse reactions. </li>
    <li>The maximum recommended dose of 50 mg protamine is sufficient to reverse UHF in most settings. </li>
</ul>
<p><em>Low Molecular Weight Heparin (LMWH)</em></p>
<ul style="list-style-type: disc;">
    <li>LMWH administration within 8 hours of the time of requirement for correction of anticoagulation: give protamine sulphate (1 mg per 100 anti-Xa units of LMWH). If ineffective, consider further protamine sulphate 0.5 mg per 100 anti-Xa units (<strong>2C</strong>). Protamine sulphate should be given slower than 5 mg/min to minimize the risk of adverse reactions. </li>
    <li>LMWH administration greater than 8 hours from the time of requirement for correction of anticoagulation: consider smaller doses of protamine (<strong>2C</strong>). </li>
    <li>Consider recombinant activated factor VII (rFVIIa) if there is continued life-threatening bleeding despite protamine sulphate and the time frame suggests there is residual effect from the LMWH contributing to bleeding. (<strong>2C</strong>). </li>
</ul>
<p><em>Danaparoid Sodium</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for danaparoid. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
    <li>Plasmapheresis may be considered for critical bleeding. </li>
</ul>
<p><em>Fondaparinux</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for fondaparinux. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
    <li>Recombinant FVIIa should be considered for critical bleeding (<strong>2C</strong>). </li>
</ul>
<p><em>Bivalirudin</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for bivalirudin. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
    <li>Exceptionally, haemodialysis, haemofiltration or plasmapheresis may be considered for critical bleeding (<strong>2C</strong>). </li>
</ul>
<p><em>Argatroban</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for argatroban. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
</ul>
<p><strong>Oral Anticoagulants</strong></p>
<p><em>Warfarin</em></p>
<ul style="list-style-type: disc;">
    <li>All hospitals managing patients on warfarin should stock a licensed four-factor prothrombin complex concentrate (PCC) (<strong>1C</strong>). </li>
    <li>Emergency anticoagulation reversal in major bleeding should be with 25&ndash;50 U/kg four-factor PCC and 5 mg intravenous vitamin K (<strong>1B</strong>). </li>
    <li>Recombinant factor VIIa is not recommended for emergency anticoagulation reversal (<strong>1B</strong>). </li>
    <li>Fresh frozen plasma produces suboptimal anticoagulation reversal and should only be used if PCC is not available (<strong>1C</strong>). </li>
    <li>Anticoagulation reversal for non-major bleeding should be with 1&ndash;3 mg intravenous vitamin K (<strong>1B</strong>). </li>
    <li>Patients with an international normalized ratio (INR) &gt;5.0 but who are not bleeding should have 1&ndash;2 doses of warfarin withheld and their maintenance dose should be reduced (<strong>1B</strong>). The cause of the elevated INR should be investigated (<strong>1C</strong>). </li>
    <li>Asymptomatic patients with an INR of &ge;8.0 should receive 1&ndash;5 mg of oral vitamin K (<strong>1B</strong>). The INR should be rechecked the following day in case an additional dose of vitamin K is required. </li>
    <li>For surgery that requires reversal of warfarin and that can be delayed 6&ndash;12 hours, the INR can be corrected by giving intravenous vitamin K. For surgery that requires reversal of warfarin and which cannot be delayed for vitamin K to have time to take effect, the INR can be corrected by giving PCC and intravenous vitamin K. PCC should not be used to enable elective or non-urgent surgery (<strong>2C</strong>). </li>
</ul>
<p><em>Other Vitamin K Antagonists</em></p>
<ul style="list-style-type: disc;">
    <li>Emergency reversal of the effect of phenprocoumon, acenocoumarol and phenindione should be with 5 mg intravenous vitamin K and 25&ndash;50 units/kg four-factor PCC. </li>
    <li>For less severe bleeding or for correction of over anticoagulation, 1&ndash;5 mg of oral vitamin K is sufficient. </li>
</ul>
<p><em>Direct Oral Thrombin Inhibitors &ndash; Dabigatran</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for dabigatran. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
    <li>In bleeding patients who have taken a dose of dabigatran in the last 2 hours, consider oral activated charcoal to prevent further absorption (<strong>2C</strong>). </li>
    <li>If rapidly deployable, haemodialysis, haemofiltration and charcoal haemoperfusion offer the possibility of enhanced clearance of the active drug (<strong>2C</strong>). </li>
    <li>In situations with ongoing life-threatening bleeding PCC, activated prothrombin complex concentrate (APCC), and rFVIIa should be considered (<strong>2C</strong>). </li>
</ul>
<p><em>Direct Oral Xa Inhibitors &ndash; Rivaroxaban and Apixaban</em></p>
<ul style="list-style-type: disc;">
    <li>There is no specific antidote for rivaroxaban. Management of bleeding should be through cessation of treatment and general haemostatic measures (<strong>2C</strong>). </li>
    <li>In situations with ongoing life-threatening bleeding, PCC, APCC and rFVIIa should be considered (<strong>2C</strong>). </li>
</ul>
<p><strong>Anti-platelet Drugs</strong></p>
<ul style="list-style-type: disc;">
    <li>Decisions to withhold anti-platelet drugs or to administer pro-haemostatic agents should be made after a careful multi-disciplinary assessment of the risks and benefits of intervention. (<strong>1C</strong>). </li>
    <li>Bleeding in patients during treatment with aspirin, P2Y<sub>12</sub> antagonists or glycoprotein (GP) IIa/IIIb inhibitors should be managed in the first instance with general haemostatic measures. If necessary, drug cessation and reversal of the effect of coprescribed anticoagulants should also be considered (<strong>2C</strong>). </li>
    <li>Platelet transfusion (2&ndash;3 adult doses) should be considered as an additional measure for critical bleeding or prevention of bleeding before emergency surgery (<strong>2C</strong>). </li>
    <li>Platelet transfusion should be considered to prevent bleeding in severe thrombocytopenia (&lt;10 x 10<sup>9</sup>/l) caused by abciximab (<strong>2C</strong>). </li>
</ul>
<p><strong>Fibrinolytic Drugs</strong></p>
<p>For major bleeding (e.g., intracerebral) within 48 hours of administration, the task force recommends:</p>
<ul style="list-style-type: disc;">
    <li>Stop infusion of fibrinolytic drugs and other antithrombotic drugs (<strong>1C</strong>). </li>
    <li>Administer fresh frozen plasma 12 ml/kg (<strong>2C</strong>). </li>
    <li>Administer intravenous tranexamic acid 1 g tds (<strong>2C</strong>). </li>
    <li>If there is depletion of fibrinogen, administer cryoprecipitate or fibrinogen concentrate (<strong>2C</strong>). </li>
    <li>Further therapy should be guided by results of coagulation tests (<strong>2C</strong>). </li>
</ul>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong>:</p>
<p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong>: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong>: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong>: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.</p>
<p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Bleeding during antithrombotic therapy</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Anesthesiology</p>
                    <p>Cardiology</p>
                    <p>Critical Care</p>
                    <p>Emergency Medicine</p>
                    <p>Hematology</p>
                    <p>Internal Medicine</p>
                    <p>Pharmacology</p>
                    <p>Surgery</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Clinical Laboratory Personnel</p>
                    <p>Hospitals</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To guide healthcare professionals in the United Kingdom&nbsp;on the management of patients receiving antithrombotic drugs who experience significant bleeding or who require emergency surgery or an invasive procedure</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>All patients receiving antithrombotic agents who are bleeding or are at risk for bleeding</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Management of bleeding associated with parenteral anticoagulants
    <ul style="list-style-type: disc;">
        <li>Cessation of anticoagulant treatment </li>
        <li>General haemostatic measures </li>
        <li>Protamine sulphate (for reversing unfractionated heparin and low molecular weight heparin) </li>
        <li>Recombinant activated factor VII (rFVIIa) </li>
        <li>Haemodialysis, haemofiltration, or plasmapheresis for critical bleeding </li>
    </ul>
    </li>
    <li>Management of bleeding associated with oral anticoagulants
    <ul style="list-style-type: disc;">
        <li>Reversal with four-factor prothrombin complex concentrate (PCC) </li>
        <li>Oral or intravenous vitamin K </li>
        <li>Fresh frozen plasma (if PCC is not available) </li>
        <li>Withholding doses of warfarin in patients with international normalized ratio (INR) &gt;5 but no bleeding </li>
        <li>Cessation of treatment and general haemostatic measures </li>
        <li>Oral activated charcoal to prevent further anticoagulant absorption </li>
        <li>Haemodialysis, haemofiltration, and charcoal haemoperfusion </li>
        <li>In situations with ongoing life-threatening bleeding: PCC, activated prothrombin complex concentrate (APCC), and rFVIIa </li>
    </ul>
    </li>
    <li>Management of bleeding associated with oral antiplatelets
    <ul style="list-style-type: disc;">
        <li>Withholding antiplatelet drugs or administering pro-haemostatic agents after a careful multi-disciplinary assessment of the risks and benefits of intervention </li>
        <li>General haemostatic measures </li>
        <li>Drug cessation and reversal of the effect of coprescribed anticoagulants </li>
        <li>Platelet transfusion for critical bleeding, prevention of bleeding before emergency surgery, or prevention of bleeding in severe thrombocytopenia caused by abciximab </li>
    </ul>
    </li>
    <li>Management of major bleeding associated with fibrinolytics
    <ul style="list-style-type: disc;">
        <li>Stopping infusion of fibrinolytic drugs and other antithrombotic drugs </li>
        <li>Fresh frozen plasma </li>
        <li>Intravenous tranexamic acid </li>
        <li>Cryoprecipitate or fibrinogen concentrate </li>
        <li>Further therapy guided by results of coagulation tests </li>
    </ul>
    </li>
</ol></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Morbidity </li>
    <li>Mortality </li>
    <li>Reversal of anticoagulant effect </li>
    <li>Bleeding, haemorrhagic, and thrombotic risks </li>
    <li>Stroke </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Hand-searches of Published Literature (Primary Sources)</p>
                    <p>Hand-searches of Published Literature (Secondary Sources)</p>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>The MEDLINE and EMBASE databases were searched systematically for publications in English from 1966 to June 2011 and 1980 to June 2011, respectively, using the following strategy: Approved and proprietary names of the antithrombotic agents described in the guideline were combined with terms relating to antidote, reversal, haemorrhage, (activated) prothrombin complex concentrate, factor VIII inhibitor bypass activity, Beriplex, Octaplex, recombinant activated factor VII, Novoseven, fresh frozen plasma, tranexamic acid, antifibrinolytic, platelet transfusion, and desmopressin. Identified papers were also searched for additional references.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong>: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong>: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong>: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to quote levels and grades of evidence (see the "Rating Scheme for the Strength of the Evidence" field).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>The guideline group was selected to be representative of United Kingdom-based medical experts.</p>
<p>The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The guideline was reviewed by a sounding board of approximately 50 United Kingdom haematologists, the British Committee for Standards in Haematology, and the British Society for Haematology Committee and comments incorporated where appropriate.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for most recommendations (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate management of bleeding in patients receiving antithrombotic agents</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Recombinant activated factor VII is often considered as a last resort when all other measures have failed and the risks and benefits are carefully documented. </li>
    <li>Prothrombin complex concentrate (PCC) and activated prothrombin complex concentrate (APCC) agents may increase thrombosis risk although this has not been evaluated in large-scale meta-analyses. </li>
    <li>Protamine can cause severe allergic reactions, including anaphylaxis, hypotension, bronchospasm and skin reactions in up to 10% of patients. Risk factors are previous exposure to protamine sulphate (including protamine-containing insulin preparations), rate of administration, vasectomy, and fish allergy. </li>
    <li>Many patients who are prescribed anti-platelet drugs are at high risk of arterial thrombosis. Therefore, the safety of anti-thrombotic drug withdrawal and pro-haemostatic interventions should be considered carefully through a multi-disciplinary risk assessment. </li>
    <li>Platelet transfusion may be considered for emergency reversal of the anti-platelet effect but may confer a risk of arterial thrombosis. </li>
</ul></p>

            </div>
                <h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Contraindications</a></h3>
                    <p><div class="content_para"><p>Desmopressin is relatively contraindicated in patients with cardiovascular disease, and there is no evidence to support efficacy in this patient group.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Staying Healthy</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Safety</p>
                    <p>Timeliness </p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013 Jan;160(1):35-46. <a href="https://web.archive.org/web/20180712194818/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23116425" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712194818im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Jan</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>British Society for Haematology Guidelines - Professional Association</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>British Committee for Standards in Haematology</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Writing Group Members</em>: Mike Makris, Department of Cardiovascular Science, University of Sheffield and Sheffield Haemophilia and Thrombosis Centre, Sheffield Teaching Hospitals NHS Trust, Sheffield; Joost J. Van Veen, Sheffield Haemophilia and Thrombosis Centre, Sheffield Teaching Hospitals NHS Trust, Sheffield; Campbell R. Tait, Department of Haematology, Glasgow Royal Infirmary, Glasgow; Andrew D. Mumford, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol; Mike Laffan, Imperial College Academic Health Sciences Centre, Hammersmith Hospital, London</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: Available from the <a href="/web/20180712194818/https://www.guideline.gov/Home/Disclaimer?id=38947&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.bcshguidelines.com%2fdocuments%2fbleeding_on_antithrombotics_Makris_2012.pdf" title="British Committee for Standards in Haematology Web site">British Committee for Standards in Haematology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712194818im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the British Committee for Standards in Haematology; Email: <a href="https://web.archive.org/web/20180712194818/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a> </p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on January 15, 2013. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: <a href="https://web.archive.org/web/20180712194818/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a>.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712194818/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712194818/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712194818/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712194818/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712194818/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712194818/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712194818/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712194818/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712194818/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712194818/https://www.guideline.gov/disclaimer?id=38947&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712194818/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712194818/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712194818/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712194818/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712194818/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712194818/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712194818/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712194818/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712194818/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712194818/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712194818/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712194818/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712194818/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712194818/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712194818im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712194818/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712194818/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712194818js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712194818js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 19:48:18 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:36:03 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 432.079 (3)
  esindex: 0.014
  captures_list: 453.33
  CDXLines.iter: 16.089 (3)
  PetaboxLoader3.datanode: 59.062 (4)
  exclusion.robots: 0.306
  exclusion.robots.policy: 0.284
  RedisCDXSource: 0.817
  load_resource: 25.9
-->